| Health News |
1. |
A hearty cup of tea? Monday, 05 July 2010A hearty cup of tea? |
2. |
Vitamin D deficiency linked to autoimmune diseases and some cancers Monday, 30 August 2010Scientists have found that vitamin D deficiency plays a key role in causing autoimmune diseases, some cancers and type 1 diabetes, after scientists found over 200 genes that it directly influences.
Research recently published in the journal Genome Research, adds weight to the theory that vitamin D deficiency plays a key role in causing autoimmune diseases, after scientists found over 200 genes that it directly influences.
The researchers created a map of the specific locations on the human genome where vitamin D binds to DNA through proteins called vitamin D receptors. Vitamin D activates these receptors and influences the behaviour of genes that are associated with particular characteristics. The study showed that the vitamin D receptor was found in over 2,700 binding sites. Many of these sites were near genes that are associated with common autoimmune diseases and certain types of cancer.
In particular, the researchers found that vitamin D had a significant effect on genes associated with multiple sclerosis, Crohn’s disease and type 1 diabetes. Vitamin D receptor binding was also found in regions on the genome that are linked with cancers such as leukaemia and colorectal cancer.
Vitamin D is produced naturally by your body when your skin is exposed to sunlight. Many people don’t get enough from these sources. This is especially true if you live in a region that is nearer to the North or South Pole than to the equator (for example the UK, Canada or southern Argentina), where the sunlight needed to make vitamin D is only strong enough during the summer.
It’s already well known that vitamin D deficiency affects bone development, leading to conditions such as rickets, but this study supports previous research showing that vitamin D plays a role in the development of other diseases. Bupa recommends taking vitamin D supplements to reduce the chance of developing cancer by 26 percent. Taking at least 1,500 to 2,000 international units (IU) a day, which equates to three to four high-strength capsules (12.5 micrograms/capsule),will reduce your risk of developing a number of cancers as well as various bone-related conditions such as osteoporosis and osteomalacia.
Dr Virginia Warren, Assistant Medical Director at Bupa, commented on the research: “It is exciting that these researchers have shown that vitamin D is involved in determining the extent to which more than 200 genes are turned on. Vitamin D insufficiency is common in the UK and deficiency happens too. Optimal levels of vitamin D can be achieved with supplements and/or spending time in summer sun without sunscreen but being careful not to let the skin get red or burn.”
Key facts:
|
3. |
1,400 'Pressure Stations' set up for "Know Your Numbers Week" Monday, 30 August 20101,400 'Pressure Stations' set up to support the Blood Pressure Associations "Know Your Numbers Week"
One in three UK adults have high blood pressure, but Blood Pressure Association research found that almost three quarters of adults do not know their blood pressure.
Know your Numbers! is the Blood Pressure Association's flagship awareness campaign. It encourages adults across the UK to know their blood pressure numbers and take the necessary action to reach and maintain a healthy blood pressure.
The highlight is Know your Numbers! Week, the nation's largest annual blood pressure testing and awareness event. This takes place in the second week of September each year and provides free checks for around 250,000 adults across the UK. Since its launch in 2001, Know your Numbers! Week has ensured more than 1.5million people have had their blood pressure checked so that they know their blood pressure numbers in the same way as their height and weight.
Know your Numbers! Week involves hundreds of nationwide organisations signing up to provide free blood pressure tests and information at venues known as Pressure Stations. Pressure Stations are located throughout the community including pharmacies, workplaces, GP surgeries, hospitals, health clubs, leisure centres, shopping centres and supermarkets.
Know your Numbers! Week 2010 takes place fom the 13th to the 19th of September. Check with your local pharmacy and get yourself tested!
References1. Forette F, Seux M, Staessen J. Prevention of dementia in randomised double-blind placebo controlled systolic hypertension in Europe (Syst-Eur) trial. The Lancet 1998;352:1346-51 2. Williams B et al.Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. The Journal of Human Hypertension 2004;18 :139-185 (available on the British Hypertension Society web site at www.bhsoc.org) 3.The Annual Report of the Chief Medical Officer of the Department of Health 2001 (www.doh.gov.uk) 4.He F, MacGregor G.Cost of poor blood pressure control in the UK : 62 000 unnecessary deaths per year. Journal of Human Hypertension 2003; 17: 455-457 (www.nature.com/jhh/) 5. Health Survey for England 2003. Department of Health publication available at www.dh.gov.uk 6. National Institutes of Health and National Heart, Lung and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of high blood pressure 2003 (www.nhlbi.nih.gov/
|
4. |
New trials on existing medicine show potential to prevent heart failure Monday, 30 August 2010Trial results have shown that an existing £10 a week pill for chest pains has the potential to save the lives of thousands of heart failure patients and save the NHS milions in the cost of hospital admissions.
Conservative estimates suggest that up to 10,000 deaths a year in the UK could be prevented.
One expert described the evidence as a "significant breakthrough" and said it would compel him to change his clinical practice.
The drug, ivabradine, is already available in the UK for Angina, the pain caused by insufficient blood reaching the heart. However, only around 10% of treated angina patients are prescribed it.
At a recent meeting of experts in Stockholm trial results suggested that ivabradine could be resurrected as a cost-effective treatment for many thousands of patients with moderate to severe heart failure. The drug cut the risk of death from heart failure by 26% in the patient population studied over a two year period. It had a similar impact on the likelihood of being admitted to hospital because of worsening symptoms.
More than 700,000 people over the age of 45 live with heart failure, which occurs when damage to the heart leaves it too weak to pump blood efficiently round the body.
An estimated 68,000 new cases are diagnosed each year. Heart failure causes symptoms of fatigue, breathlessness, increased heart rate, and swollen ankles. It can lead to serious complications, and around 40% of those affected are dead after a year.
Heart failure soaks up 1% to 2% of the total NHS budget, with direct medical costs alone amounting to £625 million a year.
The Shift (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) trial involved more than 6,500 patients in 37 countries already on standard treatments such as beta-blocker drugs.
|
5. |
Monday, 05 July 2010 A number of newspapers have covered the story of a new blood test to predict when the menopause will occur which “could close the baby gap” by telling women how long they will remain fertile for. They reported on the hormone-based menopause test, saying that home testing kits could be available in a few years.
The news is based on a study that has been presented at fertility conference, although because it is unpublished it is difficult to assess the methods and quality of the research.
It is important to stress that a woman’s fertility level and ability to conceive start to decline long before her periods stop and, therefore, a test predicting menopause may be of limited value in this area. Also, fertility levels are affected by other factors, such as blocked ovarian tubes or the quality of a man’s sperm. The limited information available suggests further testing will be needed and although the test may have a role in predicting early menopause, further results are needed to confirm this. The reports are based on a press release and conference abstract presented at the 2010 conference of the European Society of Human Reproduction and Embryology. Only limited details of the study carried out by researchers from Shaheed Beheshti University of Medical Sciences in Iran were presented. No information is available as to if or when the research may be published in a peer-reviewed journal, or about how the research was funded. Most papers also published comments from independent experts, who set the research in context and addressed the fact that such a test is only of limited use to most women because fertility levels start to fall well before the menopause occurs. A home testing kit may be on sale within three years. It was not reported in any of the stories that the information was based on a conference abstract and press release and that the full results have not yet been published.
This research aimed to test a statistical model developed to predict the age at which the menopause would occur. The model is based on assessing levels of a hormone called anti-mullerian hormone (AMH), which is produced by the ovaries. AMH controls the development of ovarian follicles from which eggs develop, and some experts have suggested it could be a marker for ovarian function. The researchers wanted to test whether measuring AMH at various ages could predict when women would reach the menopause.
Only limited information is available on the methods used in this research. However according to the abstract and press release, the researchers took blood samples to measure blood levels of AMH in 266 women, aged 20-49, randomly selected from a larger, prospective cohort study called the Tehran Lipid and Glucose Study. This ongoing study was looking at cardiovascular risk factors among the Iranian population.
In this smaller study, the researchers measured AMH levels twice more, at three-yearly intervals. They also collected information on the women’s reproductive background and reproductive history. They then developed and tested a statistical model for estimating the women’s age at menopause using a single measurement of AMH in blood samples.
The researchers say they found a “high degree of correlation” between the estimated ages at menopause provided by their formula model and the actual age at menopause seen in a subgroup of 63 women who reached menopause during the study. The average difference between the predicted age using the model and the women’s actual age was only a third of a year and the maximum margin of error of three to four years.
Using this statistical model, the researchers say they were able to identify the specific AMH levels at different ages (20, 25 and 30 years) that would predict if women were likely to have an early menopause (before 45) or reach menopause over 50 years. Among the group studied, the average age at the menopause was 52 years.
Conclusion
As the research has not yet been published and subjected to peer review and with the lack of sufficient details it must be treated with caution. This was a small study carried out over a limited period (about six years), which tested whether levels of AMH in women of reproductive age could be used to predict the age they will reach the menopause. It seems to have been designed with a reasonable cut-off point set for the test, the first step in preparing a potential test for clinical use.
If validated by further studies, such a test could be particularly useful in predicting early menopause, giving women who may experience it time to plan their future and balance careers with family.
The fact that so far only 63 women actually reached menopause in the study and only three of them were under 45, means the mathematical formula has only undergone limited testing. It should be stressed that until there are larger studies following women from the age of 20 to the age they actually reach menopause, the method the researchers used has not been proven.
It will be important to follow up this initial study with others, setting a cut-off point that can establish the sensitivity and specificity of the test. What is needed are statistical measures that relate to the number of women correctly identified by the test as going on to an early menopause (or late menopause) and also the number of women incorrectly identified or predicted as heading for early or late menopause when they do not. These results, when published, will help decide the true value of the test.
Links to the research
|